The vicious cycle of apoptotic β-cell death in type 1 diabetes

Immunology and Cell Biology

Volumn 85, Issue 8, 2007, Pages 582-589

  Kaminitz, Ayelet ^a   Stein, Jerry ^a   Yaniv, Isaac ^a   Askenasy, Nadir ^a  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Autoimmune insulitis; B cell apoptosis; Cytokines; Pathophysiology; Type 1 diabetes

Indexed keywords

CHEMOKINE; CYTOKINE;

APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; CELL DEATH; EXPERIMENTAL STUDY; IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; LOCAL LYMPH NODE ASSAY; NONHUMAN; PANCREAS ISLET BETA CELL; REVIEW; SENSITIVITY ANALYSIS; STATISTICAL SIGNIFICANCE;

ANIMALS; APOPTOSIS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; HUMANS; INSULIN-SECRETING CELLS;

EID: 36849089218     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/sj.icb.7100093     Document Type: Review

References (137)

1. Trudeau JD, Dutz JP, Arany E, Hill DJ, Fieldus WE, Finegood DT. Neonatal beta-cell apoptosis: a trigger for autoimmune diabetes? Diabetes 2000; 49: 1-7.
2. Faideau B, Larger E, Lepault F, Carel JC, Boitard C. Role of {beta}-cells in type 1 diabetes pathogenesis. Diabetes 2005; 54 (Suppl 2): S87-S96.
3. Pearl-Yafe M, Iskovich S, Kaminitz A, Stein J, Yaniv I, Askenasy N. Does physiological β cell turnover initiate autoimmune diabetes in the regional lymph nodes? Autoim Rev 2006; 5: 338-343.
4. Ludewig B, Odermatt B, Ochsenbein AF, Zinkernagel RM, Hengartner H. Role of dendritic cells in the induction and maintenance of autoimmune diseases. Immunol Rev 1999; 169: 45-54.
5. Pearl-Yafe M, Kaminitz A, Yolcu ES, Yaniv I, Stein J, Askenasy N. Pancreatic islets under attack: cellular and molecular effectors. Curr Pharm Des 2007; 13: 749-760.
6. Jun HS, Yoon CS, Zbytnuik L, van Rooijen N, Yoon JW. The role of macrophages in T cell-mediated autoimmune diabetes in nonobese diabetic mice. J Exp Med 1999; 189: 347-358.
7. Cvetkovic I, Al-Abed Y, Miljkovic D, Maksimovic-Ivanic D, Roth J, Bacher M et al. Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes. Endocrinology 2005; 146: 2942-2951.
8. Katz JD, Benoist C, Mathis D. T helper cell subsets in insulin-dependent diabetes. Science 1995; 268: 1185-1188.
9. Filippi C, Bresson D, Herrath M. Antigen-specific induction of regulatory T cells for type 1 diabetes therapy. Int Rev Immunol 2005; 24: 341-360.
10. Goudy KS, Tisch R. Immunotherapy for the prevention and treatment of type 1 diabetes. Int Rev Immunol 2005; 24: 307-326.
11. Katz JD, Wang B, Haskins K, Benoist C, Mathis D. Following a diabetogenic T cell from genesis through pathogenesis. Cell 1993; 74: 1089-1100.
12. Hoglund P, Mintern J, Waltzinger C, Heath W, Benoist C, Mathis D. Initiation of autoimmune diabetes by developmentally regulated presentation of islet cell antigens in the pancreatic lymph nodes. J Exp Med 1999; 189: 331-339.
13. Gagnerault MC, Luan JJ, Lotton C, Lepault F. Pancreatic lymph nodes are required for priming of β cell reactive T cells in NOD mice. J Exp Med 2002; 196: 369-377.
14. Kent SC, Chen Y, Bregoli L, Clemmings SM, Kenyon NS, Ricordi C et al. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature 2005; 435: 224-228.
15. Baker F, Lee M, Chien Y, Davis M. Restricted islet-cell reactive T cell repetoire of early pancreatic islet infiltrates in NOD mice. Proc Natl Acad Sci USA 2002; 99: 9374-9379.
16. + T-cell population comprises multiple antigenic specificities. Clin Immunol 2002; 105: 332-341.
17. French MB, Allison J, Cram DS, Thomas HE, Dempsey-Collier M, Silva A et al Transgenic expression of mouse proinsulin II prevents diabetes in nonobese diabetic mice. Diabetes 1997; 46: 34-39.
18. Mukherjee R, Chaturvedi P, Qin HY, Singh B. CD4+CD25+ regulatory T cells generated in response to insulin B:9-23 peptide prevent adoptive transfer of diabetes by diabetogenic T cells. J Autoimmun 2003; 21: 221-237.
19. Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D et al Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005; 435: 220-223.
20. Mathis D, Benoist C. Back to central tolerance. Immunity 2004; 20: 509-516.
21. Wilson DB. Immunology: Insulin auto-antigenicity in type 1 diabetes. Nature 2005; 438: E5-E6.
22. Jaeckel E, Lipes MA, von Boehmer H. Recessive tolerance to preproinsulin 2 reduces but does not abolish type 1 diabetes. Nat Immunol 2004; 5: 1028-1035.
23. Bottino R, Lemarchand P, Trucco M, Giannoukakis N. Gene- and cell-based therapeutics for type I diabetes mellitus. Gene Ther 2003; 10: 875-889.
24. Pearl-Yafe M, Yolcu ES, Yaniv I, Stein J, Shirwan H, Askenasy N. The dual role of Fas-ligand as an injury effector and defense strategy in diabetes and islet transplantation. BioEssays 2006; 28: 211-222.
25. Serreze DV, Leiter EH, Christianson GJ, Greiner D, Roopenian DC. Major histocompatibility complex class I-deficient NOD-B2mnull mice are diabetes and insulitis resistant. Diabetes 1994; 43: 505-509.
26. Wong FS, Visintin I, Wen L, Flavell R, Janeway Jr CA. CD8T cell clones from young NOD islets can transfer rapid onset of diabetes in NOD mice in the absence of CD4T cells. J Exp Med 1996; 183: 67-76.
27. Yoon JW, Jun HS, Santamaria P. Cellular and molecular mechanisms for the initiation and progression of beta cell destruction resulting from the collaboration between macrophages and T cells. Autoimmunity 1998; 27: 109-122.
28. Arnush M, Scarim AL, Heitmeier MR, Kelly CB, Corbett JA. Potential role of resident islet macrophage activation in the initiation of autoimmune diabetes. J Immunol 1998; 160: 2684-2691.
29. Zumsteg U, Frigerio S, Hollander GA. Nitric oxide production and Fas surface expression mediate two independent pathways of cytokine-induced murine beta-cell damage. Diabetes 2000; 49: 39-47.
30. Lenschow DJ, Herold KC, Rhee L, Patel B, Kooms A, Qin HY et al. CD28/B7 regulation of Th1 and Th2 subsets in the development of autoimmune diabetes. Immunity 1996; 5: 285-293.
31. Salomon B, Lenschow DJ, Rhee L, Ashourian N, Singh B, Sharpe A et al. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431-440.
32. Haskins K, Wegmann D. Diabetogenic T-cell clones. Diabetes 1996; 45: 1299-1305.
33. + T lymphocytes: clarification of their pathogenic roles in diabetes in the NOD mouse. Res Immunol 1997; 148: 320-327.
34. Wong FS, Janeway Jr CA. The role of CD4 vs CD8T cells in IDDM. J Autoimmun 1999; 13: 290-295.
35. Thomas HE, Kay TWH. Beta cell destruction in the development of autoimmune diabetes in the non-obese diabetic (NOD) mouse. Diabetes Metab Res Rev 2000; 16: 251-261.
36. Clare-Salzler MJ, Brooks J, Chai A, Van Herle K, Anderson C. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J Clin Invest 1992; 90: 741-748.
37. Feili-Hariri M, Dong X, Alber SM, Watkins SC, Salter RD, Morel PA. Immunotherapy of NOD mice with bone marrow-derived dendritic cells. Diabetes 1999; 48: 2300-2308.
38. Ludewig B, Odermatt B, Ochsenbein AF, Zinkernagel RM, Hengartner H. Role of dendritic cells in the induction and maintenance of autoimmune diseases. Immunol Rev 1999; 169: 45-54.
39. Shinomiya M, Fazle Akbar SM, Shinomiya H, Shinomiya H, Onji M. Transfer of dendritic cells (DC) ex vivo stimulated with interferon-gamma (IFNgamma) down-modulates autoimmune diabetes in non-obese diabetic (NOD) mice. Clin Exp Immunol 1999; 117: 38-43.
40. O'Rourke RW, Kang SM, Lower JA, Feng S, Ascher NL, Baekkeskov S et al. A dendritic cell line genetically modified to express CTLA4-Ig as a means to prolong islet allograft survival. Transplantation 2000; 69: 1440-1446.
41. Marleau AM, Singh B. Myeloid dendritic cells in non-obese diabetic mice have elevated costimulatory and T helper-1-inducing abilities. J Autoimmun 2002; 19: 23-35.
42. Feili-Hariri M, Falkner D, Gambotto A, Papworth GD, Watkins SC, Robbins PD et al. Dendritic cells transduced to express IL-4 prevent diabetes in nonobese diabetes with advanced insulitis. Hum Gene Ther 2003; 14: 13-23.
43. + T-cells in type 1 diabetes. Diabetes 2005; 54: 1407-1414.
44. Lindley S, Dayan CM, Bishop A, Roep BO, Peakman M, Tree TIM. Defective suppressor function in CD4+CD25+ T-cells from patients with type 1 diabetes. Diabetes 2005; 54: 92-99.
45. - T-cell deficiency and IDDM in NOD/Lt mice. Diabetes 1997; 46: 572-582.
46. + T cells is associated with defective peripheral tolerance in nonobese diabetic mice. Clin Immunol 2003; 107: 103-115.
47. Decallonne B, Van Etten E, Giulietti A, Casteels K, Overbergh L, Bouillon R et al. Defect in activation-induced cell death in non-obese diabetic (NOD) T lymphocytes. J Autoimmun 2003; 20: 219-226.
48. Serreze D, Gaedeke J, Leiter E. Hematopoietic stem-cell defects underlying abnormal macrophage development and maturation in NOD/Lt mice: defective regulation of cytokine receptors and protein kinase C. Proc Natl Acad Sci USA 1993; 90: 9625-9629.
49. Sen P, Bhattacharyya S, Wallet M, Wong CP, Poligone B, Sen M et al. NF-kappa B hyperactivation has differential effects on the APC function of nonobese diabetic mouse macrophages. J Immunol 2003; 170: 1770-1780.
50. Weaver Jr DJ, Poligone B, Bui T, Abdel-Motal UM, Baldwin Jr AS, Tisch R. Dendritic cells from nonobese diabetic mice exhibit a defect in NF-kappa B regulation due to a hyperactive I kappa B kinase. J Immunol 2001; 167: 1461-1468.
51. Poligone B, Weaver DJ, Sen P, Baldwin AS, Tisch R. Elevated NF-{kappa}B activation in nonobese diabetic mouse dendritic cells results in enhanced APC function. J Immunol 2002; 168: 188-196.
52. Kreuwel HT, Morgan DJ, Krahl T, Ko A, Sarvetnick N, Sherman LA. Comparing the relative role of perforin/granzyme versus Fas/Fas ligand cytotoxic pathways in CD8+ T cell-mediated insulin-dependent diabetes mellitus. J Immunol 1999; 163: 4335-4341.
53. Apostolou I, Hao Z, Rajewsky K, von Boehmer H. Effective destruction of Fas-deficient insulin-producing beta cells in type 1 diabetes. J Exp Med 2003; 198: 1103-1106.
54. Kagi D, Ho A, Odermatt B, Zakarian A, Ohashi PS, Mak TW. TNF receptor 1-dependent beta cell toxicity as an effector pathway in autoimmune diabetes. J Immunol 2003; 162: 4598-4605.
55. Savinov AY, Tcherepanov A, Green EA, Flavell RA, Chervonsky AV. Contribution of Fas to diabetes development. Proc Natl Acad Sci USA 2003; 100: 628-632.
56. Itoh N, Imagawa A, Hanafusa T, Waguri M, Yamamoto K, Iwahashi H et al. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. J Exp Med 1997; 186: 613-618.
57. Kagi D, Odermatt B, Seiler P, Zinkernagel RM, Mak TW, Hengartner H. Reduced incidence and delayed onset of diabetes in perforin-deficient nonobese diabetic mice. J Exp Med 1997; 186: 989-997.
58. Allison J, Strasser A. Mechanisms of β cell death in diabetes: a minor role for CD95. Proc Natl Acad Sci USA 1998; 95: 13818-13822.
59. Amrani A, Verdaguer J, Anderson B, Utsugi T, Bou S, Santamaria P. Perforinin-dependent beta-cell destruction by diabetogenic CD8(+) T lymphocytes in transgenic nonobese diabetic mice. J Clin Invest 1999; 103: 1201-1209.
60. Suarez-Pinzon W, Sorensen O, Bleackley RC, Elliott JF, Rajotte RV, Rabinovitch A. Beta-cell destruction in NOD mice correlates with Fas (CD95) expression on beta-cells and proinflammatory cytokine expression in islets. Diabetes 1999; 48: 21-28.
61. Amrani A, Verdaguer J, Thiessen S, Bou S, Santamaria P. IL-1alpha, IL-1beta, and IFN-gamma mark beta cells for Fas-dependent destruction by diabetogenic CD4(+) T lymphocytes. J Clin Invest 2000; 105: 459-468.
62. Herrera PL, Harlan DM, Vassalli P. A mouse CD8T cell-mediated acute autoimmune diabetes independent of the perforin and Fas cytotoxic pathways: possible role of membrane TNF. Proc Natl Acad Sci USA 2000; 97: 279-284.
63. Su X, Hu Q, Kristan JM, Costa C, Shen Y, Gero D et al. Significant role for Fas in the pathogenesis of autoimmune diabetes. J Immunol 2000; 164: 2523-2532.
64. Suarez-Pinzon WL, Power RF, Rabinovitch A. Fas ligand-mediated mechanisms are involved in autoimmune destruction of islet β cells in non-obese diabetic mice. Diabetologia 2000; 43: 1149-1156.
65. Vence L, Benoist C, Mathis D. Fas deficiency prevents type 1 diabetes by inducing hyporesponsiveness in islet β-cell reactive T-cells. Diabetes 2004; 53: 2797-2803.
66. Kim S, Kim KA, Hwang DY, Lee TH, Kayagaki N, Yagita H et al. Inhibition of autoimmune diabetes by Fas ligand: the paradox is solved. J Immunol 2000; 164: 2931-2936.
67. Yang X, Tisch R, Singer SM, Cao ZA, Liblau RS, Schreiber RD et al. Effect of tumor necrosis factor {alpha} on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J Exp Med 2004; 180: 995-1004.
68. Askenasy N, Yolcu ES, Yaniv I, Shirwan H. Induction of tolerance using Fas ligand: a double-edged immunomodulator. Blood 2005; 105: 1396-1404.
69. Green EA, Eynon EE, Flavell RA. Local expression of TNFa in neonatal NOD mice promotes diabetes by enhancing presentation of islet antigens. Immunity 1998; 9: 733-743.
70. Christen U, Von Herrath MG. Apoptosis of autoreactive CD8 lymphocytes as a potential mechanism for the abrogation of type 1 diabetes by islet-specific TNF-alpha expression at a time when the autoimmune process is already ongoing. Ann NY Acad Sci 2002; 958: 166-169.
71. Allison J, Georgiou HM, Strasser A, Vaux DL. Transgenic expression of CD95 ligand on islet beta cells induces a granulocytic infiltration but does not confer immune privilege upon islet allografts. Proc Natl Acad Sci USA 1997; 94: 3943-3947.
72. Kang SM, Schneider DB, Lin Z, Hanahan D, Dichek DA, Stock PG et al. Fas ligand expression in islets of Langerhans does not confer immune privilege and instead targets them for rapid destruction. Nat Med 1997; 3: 738-743.
73. Silva DG, Petrovsky N, Socha L, Slattery R, Gatenby P, Charlton B. Mechanisms of accelerated immune-mediated diabetes resulting from islet beta cell expression of a Fas ligand transgene. J Immunol 2003; 170: 4996-5002.
74. Petrovsky N, Silva D, Socha L, Slattery R, Charlton B. The role of Fas ligand in beta cell destruction in autoimmune diabetes of NOD mice. Ann NY Acad Sci 2002; 958: 204-208.
75. Kaneto H, Fujii J, Seo HG, Suzuki K, Matsuoka T, Nakamura M et al. Apoptotic cell death triggered by nitric oxide in pancreatic beta-cells. Diabetes 1995; 44: 733-738.
76. Yamada K, Takane-Gyotoku N, Yuan X, Ichikawa F, Inada C, Nonaka K. Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia 1996; 39: 1306-1312.
77. Stassi G, De Maria R, Trucco G, Rudert W, Testi R, Galluzzo A et al. Nitric oxide primes pancreatic beta cells for Fas-mediated destruction in insulin-dependent diabetes mellitus. J Exp Med 1997; 186: 1193-1200.
78. Kreuwel HT, Sherman LA. The role of Fas-FasL in CD8+ T-cell-mediated insulin-dependent diabetes mellitus (IDDM). J Clin Immunol 2001; 21: 15-18.
79. Nicoletti F, Di Marco R, Papaccio G, Conget I, Gomis R, Bernardini R et al. Essential pathogenic role of endogenous IL-18 in murine diabetes induced by multiple low doses of streptozotocin. Prevention of hyperglycemia and insulitis by a recombinant IL-18-binding protein: Fc construct. Eur J Immunol 2003; 33: 2278-2286.
80. Rabinovitch A, Suarez-Pinzon WL. Role of cytokines in the pathogenesis of autoimmune diabetes mellitus. Rev Endocr Metab Disord 2003; 4: 291-299.
81. Dahlen E, Dawe K, Ohlsson L, Hedlund G. Dendritic cells and macrophages are the first and major producers of TNF-alpha in pancreatic islets in the nonobese diabetic mouse. J Immunol 1998; 160: 3585-3593.
82. Sedgwick JD, Riminton DS, Cyster JG, Korner H. Tumor necrosis factor: a master-regulator of leukocyte movement. Immunol Today 2000; 21: 110-113.
83. Frigerio S, Junt T, Lu B, Gerard C, Zumsteg U, Hollander GA et al. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med 2002; 8: 1414-1420.
84. Reddy S, Ross JM. Fas and Fas ligand immunoexpression in pancreatic islets of NOD mice during spontaneous and cyclophosphamide-accelerated diabetes. Ann NY Acad Sci 2003; 1005: 166-169.
85. Sainio-Pollanen S, Liukas A, Pollanen P, Simell O. The role of CD8+ cells, cell degeneration, and Fas ligand in insulitis after intraperitoneal transfer of NOD splenocytes. Pancreas 1999; 18: 282-293.
86. Sainio-Pollanen S, Erkkila S, Alanko S, Hanninen A, Pollanen P, Simell O. The role of Fas ligand in the development of insulitis in nonobese diabetic mice. Pancreas 1998; 16: 154-159.
87. + T cells expressing CD95 ligand and secreting IL-4 in the liver. J Immunol 2002; 168: 2188-2199.
88. Zheng XX, Sanchez-Fueyo A, Sho M, Domenig C, Sayegh MH, Strom TB. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003; 19: 503-514.
89. + T-cells expressing Foxp3. Diabetes 2005; 54: 1040-1047.
90. Papaccio G, Nicoletti F, Pisanti FA, Bendtzen K, Galdieri M. Prevention of spontaneous autoimmune diabetes in NOD mice by transferring in vitro antigenpulsed syngeneic dendritic cells. Endocrinology 2000; 141: 1500-1505.
91. Naumov YN, Bahjat KS, Gausling R, Abraham R, Exley MA, Koezuka Y et al. Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets. Proc Natl Acad Sci USA 2001; 98: 13838-13843.
92. Wakkach A, Fournier N, Brun V, Breittmayer JP, Cottrez F, Groux H. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003; 18: 605-617.
93. Bruder D, Westendorf AM, Hansen W, Prettin S, Gruber AD, Qian Y et al. On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes. Diabetes 2005; 54: 3395-3401.
94. + regulatory T-cells. Diabetes 2005; 54: 78-84.
95. Mandrup-Poulsen T. The role of interleukin-1 in the pathogenesis of IDDM. Diabetologia 1996; 39: 1005-1029.
96. Eizirik DL, Pavlovic D. Is there a role for nitric oxide in beta-cell dysfunction and damage in IDDM? Diabetes Metab Rev 1997; 13: 293-307.
97. Eizirik DL, Mandrup-Poulsen T. A choice of death-the signal-transduction of immune-mediated beta-cell apoptosis. Diabetologia 2001; 44: 2115-2133.
98. Hoorens A, Stange G, Pavlovic D, Pipeleers D. Distinction between interleukin-1-induced necrosis and apoptosis of islet cells. Diabetes 2001; 50: 551-557.
99. Lee MS, Chang I, Kim S. Death effectors of beta-cell apoptosis in type 1 diabetes. Mol Genet Metab 2004; 83: 82-92.
100. Thomas HE, Irawaty W, Darwiche R, Brodnicki TC, Santamaria P, Allison J et al. IL-1 receptor deficiency slows progression to diabetes in the NOD mouse. Diabetes 2004; 53: 113-121.
101. Liu D, Pavlovic D, Chen MC, Flodstrom M, Sandler S, Eizirik DL. Cytokines induce apoptosis in beta-cells isolated from mice lacking the inducible isoform of nitric oxide synthase (iNOS-/-). Diabetes 2000; 49: 1116-1122.
102. Kagi D, Ho A, Odermatt B, Zakarian A, Ohashi PS, Mak TW. TNF receptor-1-dependent β cell toxicity as an effector pathway in autoimmune diabetes. J Immunol 1999; 162: 4598-4605.
103. Kroncke KD, Funda J, Berschick B, Kolb H, Kolb-Bachofen V. Macrophage cytotoxicity towards isolated rat islet cells: neither lysis nor its protection by nicotinamide are beta-cell specific. Diabetologia 1991; 34: 232-238.
104. Corbett JA, McDaniel ML. Intraislet release of interleukin 1 inhibits beta cell function by inducing beta cell expression of inducible nitric oxide synthase. J Exp Med 1995; 181: 559-568.
105. Mathis D, Vence L, Benoist C. Cell death during progression to diabetes. Nature 2001; 414: 792-798.
106. Pukel C, Baquerizo H, Rabinovitch A. Destruction of rat islet cell monolayers by cytokines: synergistic interaction of interferon-g, tumor necrosis factor, lymphotoxin, and interleukin 1. Diabetes 1988; 37: 133-136.
107. Irawaty W, Kay TWH, Thomas HE. Transmembrane TNF and IFN-γ induce caspase-independent death of primary mouse pancreatic beta cells. Autoimmunity 2002; 35: 369-375.
108. Mandrup-Poulsen T, Bendtzen K, Dinarello CA, Nerup J. Human tumor necrosis factor potentiates human interleukin 1-mediated rat pancreatic beta-cell cytotoxicity. J Immunol 1987; 139: 4077-4082.
109. Lin B, Zhang ZL, Yu LY, Guo LH. CMV-hFasL transgenic mice are sensitive to low doses of streptozotocin-induced type I diabetes mellitus. Acta Pharmacol Sin 2003; 24: 1199-1204.
110. Mueller C, Held W, Imboden MA, Carnaud C. Accelerated β-cell destruction in adoptively transferred autoimmune diabetes correlates with an increased expression of the genes coding for TNF-a and granzyme A in the intra-islet infiltrates. Diabetes 1995; 44: 112-117.
111. Pakala SV, Chivetta M, Kelly CB, Katz JD. In autoimmune diabetes the transition from benign to pernicious insulitis requires an islet cell response to tumor necrosis factor a. J Exp Med 1999; 189: 1053-1062.
112. Lee MS, Kim S, Chung JH, Lee MK, Kim KW. Fas is expressed in murine pancreatic islet cells and an insulinoma cell line but does not mediate their apoptosis in vitro. Autoimmunity 1999; 29: 189-199.
113. Yolcu SE, Askenasy N, Singh PN, Lamhamedi Cherradi SE, Shirwan H. Cell membrane modification for rapid display of proteins as a novel means of immunomodulation: FasL-decorated cells prevent islet graft rejection. Immunity 2002; 17: 795-808.
114. Thomas HE, Darwiche R, Corbett JA, Kay TW. Evidence that beta cell death in the nonobese diabetic mouse is Fas independent. J Immunol 1999; 163: 1562-1569.
115. Walter U, Franzke A, Sarukhan A, Zober C, von Boehmer H, Buer J et al. Monitoring gene expression of TNFR family members by beta-cells during development of autoimmune diabetes. Eur J Immunol 2000; 30: 1224-1232.
116. Moriwaki M, Itoh N, Miyagawa J, Yamamoto K, Imagawa A, Yamagata K et al. Fas and Fas ligand expression in inflamed islets in pancreas sections of patients with recent-onset type I diabetes mellitus. Diabetologia 1999; 42: 1332-1340.
117. Darwiche R, Chong MM, Santamaria P, Thomas HE, Kay TW. Fas is detectable on beta cells in accelerated, but not spontaneous, diabetes in nonobese diabetic mice. J Immunol 2003; 170: 6292-6297.
118. Loweth AC, Williams GT, James RF, Scarpello JH, Morgan NG. Human islets of Langerhans express Fas ligand and undergo apoptosis in response to interleukin-1beta and Fas ligation. Diabetes 1998; 47: 727-732.
119. Maedler K, Spinas GA, Lehmann R, Sergeev P, Weber M, Fontana A et al. Glucose induces b-cell apoptosis via upregulation of the Fas-receptor in human islets. Diabetes 2001; 50: 1683-1690.
120. Kay TW, Darwiche R, Irawaty W, Chong MM, Pennington HL, Thomas HE. The role of cytokines as effectors of tissue destruction in autoimmunity. Adv Exp Med Biol 2003; 520: 73-86.
121. Maedler K, Fontana A, Ris F, Sergeev P, Toso C, Oberholzer J et al. FLIP switches Fas-mediated glucose signaling in human pancreatic beta cells from apoptosis to cell replication. Proc Natl Acad Sci USA 2002; 99: 8236-8241.
122. Donath MY, Storling J, Maedler K, Mandrup-Poulsen T. Inflammatory mediators and islet β-cell failure: a link between type 1 and type 2 diabetes. J Mol Med 2003; 81: 455-470.
123. Kwon G, Corbett JA, Rodi CP, Sullivan P, McDaniel ML. Interleukin-1 beta-induced nitric oxide synthase expression by rat pancreatic beta-cells: evidence for the involvement of nuclear factor kappa B in the signaling mechanism. Endocrinology 1995; 136: 4790-4795.
124. Flodstrom M, Welsh N, Eizirik DL. Cytokines activate the nuclear factor kappa B (NFkappa B) and induce nitric oxide production in human pancreatic islets. FEBS Lett 1996; 385: 4-6.
125. Darville MI, Eizirik DL. Cytokine induction of Fas gene expression in insulin-producing cells requires the transcription factors NF-kappaB and C/EBP. Diabetes 2001; 50: 1741-1748.
126. Zeender E, Maedler K, Bosco D, Berney T, Donath MY, Halban PA. Pioglitazone and sodium salicylate protect human beta-cells against apoptosis and impaired function induced by glucose and interleukin-1 beta. J Clin Endocrinol Metab 2004; 89: 5059-5066.
127. Maedler K, Sergeev P, Ris F, Oberholzer J, Joller-Jemelka HI, Spinas GA et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002; 110: 851-860.
128. Maedler K, Sergeev P, Ehses JA, Mathe Z, Bosco D, Berney T et al. Leptin modulates cell expression of IL-1 receptor antagonist and release of IL-1 in human islets. Proc Natl Acad Sci USA 2004; 101: 8138-8143.
129. Papaccio G, Graziano A, D'Aquino R, Valiante S, Naro F. A biphasic role of nuclear transcription factor (NF)-kappaB in the islet beta-cell apoptosis induced by interleukin (IL)-1beta. J Cell Physiol 2005; 204: 124-130.
130. Elouil H, Cardozo AK, Eizirik DL, Henquin JC, Jonas JC. High glucose and hydrogen peroxide increase c-Myc and haeme-oxygenase 1 mRNA levels in rat pancreatic islets without activating NFkB. Diabetologia 2005; 48: 496-505.
131. Welsh N, Cnop M, Kharroubi I, Bugliani M, Lupi R, Marchetti P et al. Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets? Diabetes 2005; 54: 3238-3244.
132. Apostolou I, Hao Z, Rajewsky K, von Boehmer H. Effective destruction of Fas-deficient insulin-producing β cells in type 1 diabetes. J Exp Med 2003; 198: 1103-1106.
133. Leiter EH, Christianson GJ, Serreze DV, Ting AT, Worthen SM. MHC antigen induction by interferon gamma on cultured mouse pancreatic beta cells and macrophages. Genetic analysis of strain differences and discovery of an 'occult' class I-like antigen in NOD/Lt mice. J Exp Med 1989; 170: 1243-1262.
134. Thomas HE, Parker JL, Schreiber RD, Kay TW. IFN-gamma action on pancreatic beta cells causes class I MHC upregulation but not diabetes. J Clin Invest 1998; 102: 1249-1257.
135. Hamilton-Williams EE, Palmer SE, Charlton B, Slattery RM. Beta cell MHC class I is a late requirement for diabetes. Proc Natl Acad Sci USA 2003; 100: 6688-6693.
136. Yamanouchi J, Verdaguer J, Han B, Amrani A, Serra P, Santamaria P. Cross-priming of diabetogenic T cells dissociated from CTL-induced shedding of beta cell autoantigens. J Immunol 2003; 171: 6900-6909.
137. Kay T, Parker J, Stephens L, Thomas H, Allison J. RIP-β2- microglobulin transgene expression restores insulitis, but not diabetes, in β2-microglobulinnull nonobese diabetic mice. J Immunol 1996; 157: 3688-3693.